Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Humanized Biomimetic Nanovesicles for Neuron Targeting.
Zinger A, Cvetkovic C, Sushnitha M, Naoi T, Baudo G, Anderson M, Shetty A, Basu N, Covello J, Tasciotti E, Amit M, Xie T, Taraballi F, Krencik R. Zinger A, et al. Among authors: basu n. Adv Sci (Weinh). 2021 Oct;8(19):e2101437. doi: 10.1002/advs.202101437. Epub 2021 Aug 11. Adv Sci (Weinh). 2021. PMID: 34382379 Free PMC article.
Assessing Gq-GPCR-induced human astrocyte reactivity using bioengineered neural organoids.
Cvetkovic C, Patel R, Shetty A, Hogan MK, Anderson M, Basu N, Aghlara-Fotovat S, Ramesh S, Sardar D, Veiseh O, Ward ME, Deneen B, Horner PJ, Krencik R. Cvetkovic C, et al. Among authors: basu n. J Cell Biol. 2022 Feb 9;221(4):e202107135. doi: 10.1083/jcb.202107135. Epub 2022 Feb 9. J Cell Biol. 2022. PMID: 35139144 Free PMC article.
Biomimetic cellular vectors for enhancing drug delivery to the lungs.
Evangelopoulos M, Yazdi IK, Acciardo S, Palomba R, Giordano F, Pasto A, Sushnitha M, Martinez JO, Basu N, Torres A, Hmaidan S, Parodi A, Tasciotti E. Evangelopoulos M, et al. Among authors: basu n. Sci Rep. 2020 Jan 13;10(1):172. doi: 10.1038/s41598-019-55909-x. Sci Rep. 2020. PMID: 31932600 Free PMC article.
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Among authors: basu n. Lancet Rheumatol. 2024 May 8:S2665-9913(24)00065-1. doi: 10.1016/S2665-9913(24)00065-1. Online ahead of print. Lancet Rheumatol. 2024. PMID: 38734019
619 results